Second Wave of COVID-19 Vaccines Could Resolve Vaccine Inequity

There’s one significant ray of hope for those frustrated by vaccine inequity: second-generation coronavirus vaccines are currently showing promise in clinical trials, many of which may prove highly effective as well as cheaper and easier to distribute around the world. The AKS-452 candidate produced by Massachusetts-based Akston Biosciences, for example, recently entered Phase II trials at the University Medical Center Groningen (UMCG), one of the largest hospitals in the Netherlands. Read more >>